Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Drug/Device and Device/Drug Combinations in the EU and USA (London, United Kingdom - October 18-19, 2018) - Research and Markets

Research and Markets
Posted on: 20 Dec 17

The "Drug/Device and Device/Drug Combinations in the EU and USA" conference has been added to Research and Markets' offering.

The demarcation between medicinal products and devices is becoming evermore important. In addition, with the convergence of emerging novel technologies the number of drug/device combination products and medical devices incorporating a medicinal substance are increasing.

This seminar will provide practical advice on the borderline issues concerning these combination products and provide key guidance on the regulatory strategy to follow.


Day one

09.30 Chairman's welcome

09.40 Introductory overview

- Background

- Life cycle management

- Exclusivity

- Patents

10.10 European regulatory guidance

- Life expectations of a competent authority

- Impact of the revision to the MDD

- EMEAs viewpoint management

12.30 Panel discussion on the EU regulatory requirements

13.45 Defining the regulatory approval route for your product

- Product classification

- Differences between device containing ancillary medicinal substances and medicinal products

14.30 Medical Device CE Certification - Notified Body expectations

- Devices containing ancillary medicinal substance

- Devices containing ancillary human blood derivative

- Post CE Marking expectations and changes

15.45 Highlights of major differences in documentation between:

- Device

- Drug and device

- Device and drug

16.15 Quality and non-clinical considerations for combination products

- Quality, pre-clinical and biocompatibility issues and how to address these for combination products

- What kind of non-conformance can we expect if you combine a drug and device?

Day two

09.00 Review of day one

09.05 Companion diagnostics

09.30 Clinical trial considerations

10.15 FDA's approach to combination products

- FDA's approach to combination products

- Requirements for product assignment, pre-market review and post-market regulation

- Good Manufacturing Practice (GMP) regulation

- Resources and guidance documents

- Hints and tips on good approaches

11.20 FDA's approach to combination products - (continued) Mark Kramer

12.45 Panel discussion Compare and contrast EU and USA regulations

14.15 Human tissue engineered products

- What are tissue engineered and advanced therapy combination medicinal products?

- How are these new borderline products regulated in the EU and US?

- What are the practical challenges with development of these products?

- Impact of the proposed regulation on medical devices

15.30 Post market surveillance for combination products: Vigilance or pharmacovigilance?

For more information about this conference visit

View source version on

Business Wire

Last updated on: 20/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.